-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.USD↓
Noxopharm Limited outperformed den DAX um +197 % vom 29.01.2020 bis 03.09.2021
Dir gefallen die Informationen zu Noxopharm Limited?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Noxopharm Limited?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Noxopharm Limited?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Noxopharm Limited?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
20 News & Informationen zur Noxopharm Limited Aktie
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August
Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs for ASX health stocks.
Noxopharm : Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients
Clinical Program to Expand Globally Following Positive Phase I Clinical Results
… | August 25, 2021
ASX Health Stocks: IDT shoots 20pc on COVID-19 deal with government, ImpediMed granted US FDA Breakthrough
IDT Australia jumped more than 20% after announcing that it has formalised activities with the Australian Government to assist with COVID-19 vaccine.
Noxopharm (ASX:NOX) extends COVID-19 drug program after positive results
Noxopharm (ASX:NOX) is planning to extend the trials of its COVID-19 treatment after receiving positive preliminary results from its phase one clinical trial.
Closing Bell: ASX down 2.2pc for the week
Closing Bell: ASX down 2.2pc for the week
Closing Bell: Risk off sentiment reigns again as ASX loses 0.5%
Closing Bell: Risk off sentiment reigns again as ASX loses 0.5%
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
Proactive news headlines including Tambourah Metals, Archer Materials, Lithium Australia and Noxopharm
Sydney, Aug. 11, 2021 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the…
Proactive news headlines including Burley Minerals, Highfield Resources, Poseidon Nickel and Cauldron Energy
Sydney, Aug. 09, 2021 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the…
Noxopharm (ASX:NOX) teams up with US National Cancer Institute
Noxopharm (ASX:NOX) have teamed up with the US National Cancer Institute (NCI) in hopes to find more effective treatments of brain cancer.
Market Highlights and 5 ASX Small Caps to watch on Monday
ASX small caps to watch on Monday 9 August, and highlights from Wall Street overnight. ASX stocks to watch for include Bluglass(BLG) and Noxopharm(NOX).
ASX health stocks: dorsaVi leads the pack with 12% jump on major contract extension
Micro cap medical device company dorsaVi (DVL) took the limelight this morning, jumping by 15% after saying that it has extended the contract with Medtronic
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing
ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the benchmark rose by 3%.
IRIS Metals launches $7m IPO to join Western Australia’s gold rush
IRIS Metals is set to become the latest Kookynie entrant to join the ASX boards, with its sights set on following the recent exploration successes other companies have had in the Kookynie mining camp.
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down
Noxopharm’s (ASX:NOX) DARRT-2 study gets green light from FDA
Noxopharm (ASX:NOX) advises the US Food and Drug Administration (FDA) has given the green light for its DARRT-2 study.
V-Con: Talking medical innovations and breakthrough treatments with ASX biotechs
V-Con is Stockhead’s investing focused video conference series, bringing you expert insights, panel discussions and presentations from leading analysts,
Noxopharm (ASX:NOX) secures European patent allowance for Veyonda
Noxopharm (ASX:NOX) secures European patent allowance for cancer treatment-enhancing drug candidate, Veyonda.
The Noxopharm (ASX:NOX) share price is soaring 7%
The Noxopharm Ltd (ASX: NOX) share price is gaining as the company announced it's received a notice of allowance for a European patent.
Check Up: From Moderna’s effective jabs to Patrys’ brain cancer breakthrough
Stockhead reports ASX biotech and healthcare roundup for the last fortnight. Stocks include Actinogen (ACW), Suda Pharma (SUD), and Patrys (PAB).